Category Archives: Global News Feed

New York, NY, and Tel Aviv, ISRAEL, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory, Provista Diagnostics, Inc., is expanding its onsite school sample collection programs for COVID-19 PCR testing to include MonkeyPox testing. Provista is able to test for both COVID-19 and MonkeyPox from the same saliva sample. The expansion of onsite sample collection support for schools to include MonkeyPox is designed for a situation where a school has a confirmed MonkeyPox case, whether from staff or students, and there is a desire from school administrators to screen staff and students entering the school in order to contain potential MonkeyPox outbreaks. In these situations, it is highly recommended that schools simultaneously test for COVID-19 in order to minimize the potential that students could be simultaneously infected with COVID and MonkeyPox, as has recently been reported can occur. The service is initially available in select Georgia and New Jersey districts where Provista already has established capabilities. The Company plans to expand the jurisdictions in which this service is available through sample collection partnerships in the near future.

Read more:
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced a recent publication in the Journal of Cancer Research and Clinical Oncology,1 a peer-reviewed scientific journal, supporting the Company’s ongoing clinical programs by reinforcing the foundational galectin-3 biology underlying Galecto’s approach to the inhibition of galectin-3 for the treatment of cancer.

Go here to see the original:
Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

Read more:
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

DENVER, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, today announced that it has entered into a Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor in the Company (the "Investor"). The Subscription Agreement allows the Company to issue and sell up to $10,000,000 of ordinary shares in the capital of the Company (the "Common Shares") from the treasury to the Investor, from time to time, in a series of closings (each, a “Draw Closing”) at the Company's discretion and on the terms and subject to the conditions set out in the Subscription Agreement. For each Draw Closing, the Common Shares will be issued under a shelf prospectus supplement (a "Prospectus Supplement") to the Company's short form base shelf prospectus for the province of Québec and amended and restated short form base shelf prospectus for each of the areas of Canada, except Québec dated January 28, 2022 (the "Base Shelf Prospectus").

Visit link:
Mydecine Innovations Group Announces Common Share Subscription Agreement

PHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present new clinical and translational data from cohort A4 and safety data from cohort A5 in the DesCAARTes™ trial of DSG3-CAART in a late-breaking oral presentation at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress, which is being held virtually and in person in Milan, Italy from September 7-10, 2022.

Go here to see the original:
Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years –

See the rest here:
Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

BASKING RIDGE, NJ, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it had received a deficiency letter ("Letter") from NYSE American LLC ("NYSE American" or the "Exchange") stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").

Read the rest here:
Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

Mechelen, Belgium; 29 August 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.

See more here:
Galapagos receives transparency notification from FMR LLC

IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2022 financial results.

Go here to read the rest:
Biomerica Reports Fiscal 2022 Year End Results

ENCINITAS, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will host investor meetings and provide a company overview during fireside chats at the following upcoming investor conferences:

Read more:
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences